NOTE: The content below contains the first few paragraphs of the printed article and the titles of the sidebars and boxes, if applicable.
* Pharmaceutical POOL Robert DAVIS Dr. Ludwig HANTSON Baxter International Forms Medical Products Business Baxter International has appointed Robert Davis corporate VP and president of its newly created medical products business, which combines the company’s renal and medication delivery businesses into a single global business unit. Mr. Davis previously served as corporate VP and president of Baxter’s renal business. He holds a juris doctorate from Northwestern University School of Law and a master’s degree from Northwestern University’s Kellogg Graduate School of Management. In other moves, Ludwig Hantson, Ph.D., has been appointed corporate VP and president of Baxter’s BioScience business. Mr. Hantson joined Baxter in May 2010 as corporate VP and president of the company’s international business. He received a Ph.D. in motor rehabilitation and physical therapy from the University of Louvain in Belgium. * Biotechnology POOL Dr. Sef KURSTJENS Agensys Names CEO Sef Kurstjens, M.D., Ph.D. has been appointed CEO and president of Astellas Pharma affiliate Agensys, a U.S.-based biotechnology company developing monoclonal antibody products to treat solid tumor cancers. Dr. Kurstjens succeeds retiring Agensys Founder Donald Rice, Ph.D. Dr. Kurstjens joins Agensys from Allergan, where he served as senior VP, chief medical officer and head, global drug development. He received advanced degrees in medicine and experimental physiology from University of the Witwatersrand Medical School in Johannesburg. * Biopharmaceutical POOL Dr. Kenneth FERGUSON Omeros Names Development VP Omeros, a biopharmaceutical company discovering, developing, and commercializing products focused on inflammation and disorders of the central nervous system, has named Kenneth Ferguson, Ph.D., VP, development. Dr. Ferguson brings more than 20 years of experience managing research and development organizations, including stints as VP of therapeutic development at Icos as chief operating officer and chief scientific officer of the Lilly Icos joint venture. He holds a Ph.D. in pharmacology from the University of Texas Health Science Center. Dr. Gregory FROST Dr. H. Michael SHEPARD Halozyme Therapeutics Selects CEO Halozyme Therapeutics, a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, has appointed Gregory Frost, Ph.D., president and CEO. Dr. Frost succeeds Jonathan Lim, M.D., who has resigned to pursue other opportunities. Dr. Frost co-founded Halozyme in 1999 and has led the company’s R&D efforts from discovery through FDA approval for a number of biotechnology products. He received a Ph.D. from the University of California, San Francisco. In other moves, Halozyme has promoted H. Michael Shepard, Ph.D., to chief scientific officer. Dr. Shepard joined Halozyme in 2009 as VP of discovery research. He received a Ph.D. in molecular, cellular, and developmental biology from Indiana University, where he was a Damon Runyon Cancer Research Foundation Fellow. Dr. Brian HAMILTON J. Kris PIPER Ziopharm Oncology Adds VPs Ziopharm Oncology, a biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of cancer drugs, has appointed Brian Hamilton, M.D., Ph.D., senior VP of clinical operations, with responsibility for guiding the company’s clinical programs. Dr. Hamilton was previously a senior VP and chief medical officer at Soligenix. He received an M.D. and a Ph.D. from the University of Washington, with postgraduate training in pediatrics, allergy, immunology, and oncology. In other moves, J. Kris Piper has joined Ziopharm as VP, clinical regulatory, quality, and project management. Mr. Piper has more than 30 years of industry experience in new drug development, most recently as VP at Xanthus Pharmaceuticals. He holds an M.S. in physiology from the University of California, Davis. * Device/Diagnostic POOL Dr. Walter CARNEY On-Q-ity Names Scientific Chief On-Q-ity, an oncology diagnostics company developing personalized and predictive tests to improve cancer therapy effectiveness, has appointed Walter Carney, Ph.D., chief scientific officer, overseeing all research programs and the scientific vision for the company’s proprietary technology platforms. Dr. Carney was most recently CEO of Oncogene Science. * Emerging POOL Dr. Pedro SANTABARBARA Dr. Elizabeth TREHU Infinity Pharmaceuticals Bolsters Product Development Team Infinity Pharmaceuticals, a company seeking to discover and develop small-molecule-based medicines for difficult-to-treat diseases, has made two key appointments to its executive leadership team. Pedro Santabarbara, M.D., Ph.D., has been named chief medical officer. Dr. Santabarbara joins Infinity after five years with PharmaMar. He received an M.D. and a Ph.D. from the University of Barcelona. Elizabeth Trehu, M.D., has been appointed VP, product development and medical affairs. Dr. Trehu was previously Genzyme’s VP and general manager, hematology. She holds an M.D. from New York University School of Medicine. * Agency POOL Rodrigo ALMEDIA Anne BOZZINI James GRIFFITH Bob HOLLOWAY Jennifer RAUCH Josh VOLUCK Cadient Group Continues Growth Cadient Group, a provider of digital marketing services and technology-enabled solutions for the healthcare industry, has announced a number of additions and promotions to its teams based in New York and King of Prussia, Pa. Rodrigo Almedia has joined Cadient’s New York office as a strategic engagement director, with responsibility for managing the company’s overall relationship with accounts, as well as leading the account planning and new business development. Mr. Almedia previously worked at Sudler Digital. Anne Bozzini was promoted to VP, group account director responsible for overseeing the New York-based client engagement teams. Ms. Bozzini has partnered with Cadient clients on various campaigns including premarket development, product launch, brand positioning, campaign development, and market expansion strategies. James Griffith has joined Cadient Group’s King of Prussia office as senior creative lead, with primary responsibility for overseeing operations within the creative group and facilitating integration with other departments. Mr. Griffith’s previous experience includes stints at 30 West, The Hal Lewis Group, GSW, and Roska Healthcare. In King of Prussia, Bob Holloway has been promoted to senior VP, marketing strategy, overseeing that location’s client engagement teams. With nearly 20 years of marketing and advertising experience in healthcare businesses, Mr. Holloway has worked on a wide range of products and led interactive strategy development and implementation for brands in a number of therapeutic areas. Jennifer Rauch joins Cadient Group’s New York office as a strategic engagement director responsible for managing the company’s overall relationship with accounts, as well as leading the account planning and new business development. Ms. Rauch was previously a management supervisor for both HealthEd Group and G2 Direct Digital. Josh Voluck has been promoted to strategic engagement director from senior account manager. He oversees key client relationships and strategic planning for his team’s accounts, contributes to new business development opportunities, and provides input into corporate planning decisions. Karen BECKERT Former Ogilvy & Mather Executive Joins Vox Medica Vox Medica, a communications company focused exclusively on healthcare, has appointed Karen Beckert as senior VP. Ms. Beckert brings more than 12 years of healthcare marketing expertise, as well as previous work on consumer packaged goods and financial services. She most recently served as a senior partner and executive group director for Ogilvy & Mather. Matt COLLINS Caren SPIGLAND Greg WILSON AbelsonTaylor Expands Creative Team Independent healthcare advertising agency AbelsonTaylor has made a number of additions and promotions to its creative staff. Matt Collins has been promoted to director of interactive development, from associate director of development. Mr. Collins works with the creative and account staffs and supervises the development and creation of websites, online advertising, enterprise software platforms, and digital sales aids. He received an MFA from Indiana University. Caren Spigland has been promoted to associate creative director, from senior copywriter. Ms. Spigland is working on products for the treatment of dyslipidemia and epilepsy, handling materials for both professional and DTC audiences. She holds an M.A. in comparative literature from the University of Chicago. Greg Wilson has joined AbelsonTaylor as senior art director after four years as an independent senior art director. Mr. Wilson provides direction on a variety of accounts. Nicole DEBIASE Dave KUNZE Jennifer STUTZ Natrel Communications Makes Promotions, Additions Independent, full-service healthcare advertising agency Natrel Communications has announced two additions and one promotion to its creative and account services departments. Nicole DeBiase has been appointed account group supervisor. Ms. DeBiase was previously a manager in the iMarketing group at Novartis Oncology. Dave Kunze has joined Natrel as group art supervisor. Mr. Kunze was formerly VP, group art supervisor at Pace. In other moves, Natrel has promoted Jennifer Stutz to account executive, from traffic coordinator. John HENNIGAN Flaum Partners Appoints Client Services Director Flaum Partners, a strategic marketing consultancy and agency, has named John Hennigan director, client services and partner. Mr. Hennigan has held several leadership positions in the healthcare industry that focused his multidisciplinary approach to healthcare communications. He received an MBA in marketing from Seton Hall University. Charlene Horvath LEITNER Swapna MEHTA Amy PARKE Jigna PATEL Tara RICE Melanie SMITH HealthEd Unveils Staff Additions HealthEd, a specialized agency focused on turning education into positive health outcomes, has announced a number of new additions to the company. Charlene Horvath Leitner has joined HealthEd as VP, strategic planner. Ms. Leitner was previously senior director, diabetes marketing, for Sanofi-Aventis. Swapna Mehta has been named manager, health education. Ms. Mehta previously served as program manager for the Columbia Center for Children’s Environmental Health. She received an MPH in health education and behavioral sciences from UMDNJ-School of Public Health and is a certified health education specialist. Amy Parke has been appointed management supervisor, account services. Ms. Parke joins HealthEd from Access Communications. She holds an MBA from Fairleigh Dickinson University. Jigna Patel has been appointed senior account executive, account services. Ms. Patel was most recently account executive for Euro RSCG Life Catapult. Tara Rice has joined HealthEd as manager, health education. Ms. Rice’s previous experience includes roles as health education specialist for Memorial Sloan-Kettering, program administrator of MindBody Program for NYU Medical Center, and community outreach coordinator for Visiting Nurse Healthcare System. She received an MPH in community health education from Hunter College. Melanie Smith has been named director, health education. Most recently, Ms. Smith served as associate director, public education, outreach, and communication for New York City Health and Hospitals. She earned an M.A. in public communication from American University and an MPA in health policy and management from New York University. Michael ZILLIGEN Ogilvy CommonHealth Specialty Marketing Names President Ogilvy CommonHealth Worldwide has announced the appointment of Michael Zilligen as president of Ogilvy CommonHealth Specialty Marketing, the organization’s full-service advertising and promotion agency focused on high-science and specialty markets. Mr. Zilligen oversees all operations, strategic planning, and new business initiatives for the group. He previously served as president of the medical-education unit at ProCom, which was renamed Ogilvy CommonHealth Medical Education following the June 2010 merger of Ogilvy Healthworld and CommonHealth. * CRO POOL Dr. Chris BEAVER PharmaNet Hires Immunochemistry Director PharmaNet Development Group, a global provider of clinical development services to pharmaceutical, biotechnology, generic drug, and medical device companies, has appointed Chris Beaver, Ph.D., director, immunochemistry services. Dr. Beaver is responsible for leading the immunochemistry team and expanding the company’s large-molecule services. Before joining PharmaNet, Dr. Beaver served as scientific director of ligand binding/cell based assays at another clinical research organization with macromolecule bioanalysis operations. He received a Ph.D. in neuroscience from Dalhousie University in Halifax, Canada, followed by postdoctoral training at Yale University. Dr. Charlene SANDERS Premier Research Expands Regulatory Leadership Charlene Sanders, M.D., has joined international pharmaceutical and medical device services company Premier Research Group as VP, global regulatory affairs and pediatric strategic consulting. Dr. Sanders brings more than 15 years of pharmaceutical management experience and therapeutic experience in oncology, neuroscience, pain, and pediatrics. She received an M.D. from the University of Pennsylvania School of Medicine. * Service POOL Hillary FORD Direct Medical Data Adds Practice Leader Healthcare information company Direct Medical Data has named Hillary Ford practice leader, medical publishing, collaborating with many of the top U.S. medical publishers to grow their publishing business and increase their revenue. Ms. Ford has more than 20 years of experience in medical publishing. Before joining DMD, she served as corporate sales director, special projects at Informa Healthcare. Dr. Shane N.O. WILLIAMS Egon Zehnder Expands U.S. Practice International executive search firm Egon Zehnder International has named Shane N.O. Williams, Ph.D., a consultant in its New York-based North American and global life sciences practice, where he is focusing on pharmaceutical clients in both the R&D and commercial areas. Before joining Egon Zehnder, Dr. Williams held numerous high-profile positions with Elan Pharmaceuticals, including VP of corporate strategy and business development. He received a Ph.D. from the University of Cambridge and did a postdoctoral fellowship at the Harvard-MIT Division of Health Sciences and Technology, where he conducted research in the area of regenerative medicine and tissue engineering. Raymond WRIGHT MedMeme Appoints Sales VP MedMeme, a provider of key opinion leader and competitive intelligence data to the healthcare, pharmaceutical, and biotechnical industries, has named Raymond Wright VP of sales, with responsibility for the East Coast region. Mr. Wright previously served as key account manager at Decision Resources. * Technology POOL Elizabeth RICCI PHT Strengthens Executive Team Elizabeth Ricci has joined PHT, a provider of patient reported outcomes (PRO) and electronic patient reported outcomes (ePRO) solutions, as VP, product development. Ms. Ricci was previously senior VP, products at Kadient. She received an M.S. in mathematics from Northeastern University. * Biotechnology POOL Dr. Henry LOWMAN Dr. Mark ROLFE CytomX Strengthens R&D Leadership CytomX Therapeutics, an early-stage biotechnology company focused on the development of proteolytically activated antibodies, has named industry veteran Henry Lowman, Ph.D., VP, research. Dr. Lowman joins CytomX from NGM Biopharmaceuticals, where he was director of protein sciences. Before that, Dr. Lowman spent 20 years in research and development at Genentech. He received a Ph.D. in chemistry from Purdue University. In other moves, CytomX has appointed Mark Rolfe, Ph.D., chief scientific officer. Dr. Rolfe brings more than two decades of experience in oncology drug discovery and development, most recently as chief scientific officer and interim chief medical officer at Facet Biotech, which was recently acquired by Abbott Laboratories. He received a Ph.D. from the National Institute for Medical Research in the United Kingdom and completed postdoctoral fellowships at the Imperial Cancer Research Fund (ICRF) in London and Columbia University in New York. Dr. Gerard (Rod) RIEDEL NormOxys Selects Regulatory VP NormOxys, a biotechnology company developing a novel class of small molecule drugs that enhance the body’s ability to deliver oxygen to diseased tissues, has appointed Gerard (Rod) Riedel, Ph.D., VP, regulatory affairs and program management. Dr. Riedel is responsible for NormOxys’ global regulatory strategy and its interactions with national health authorities and regulatory agencies, as well as leading and coordinating the company’s drug development programs. He joins NormOxys from Momenta Pharmaceuticals, where he most recently served as VP, regulatory affairs. * Biopharmaceutical POOL Dr. Richard GHALIE Dr. John LONGENECKER HemaQuest Announces Leadership Changes HemaQuest Pharmaceuticals, a biotechnology company focused on developing small-molecule therapeutics to treat hemoglobin-associated diseases, has announced the addition of two executives to its management team. Richard Ghalie, M.D., a board-certified hematologist and medical oncologist with more than 17 years of experience in the biopharmaceutical industry, has joined HemaQuest as chief medical officer. Dr. Ghalie’s previous experience includes serving as chief medical officer for both Novalar Pharmaceuticals and Favrille. He received a medical doctorate from the French School of Medicine in Beirut, an M.S. from the University of Paris VII, and an MBA from the University of Washington. John Longenecker, Ph.D., has been named president and CEO, succeeding HemaQuest Co-Founder Ronald Berenson, who remains a consultant to the company. Dr. Longenecker has more than 25 years of executive management experience in the biotechnology industry, including recent stints as president and CEO of Vitreoretinal Technologies and Favrille. He received a Ph.D. in biochemistry from The Australian National University in Canberra. Dr. Trevor HALLAM Sutro Biopharma Taps Scientific Chief Sutro Biopharma has appointed Trevor Hallam, Ph.D., chief scientific officer. Dr. Hallam leads ongoing efforts in the application of the biopharmaceutical company’s proprietary protein biochemical synthesis platform for the research and development of novel and biosuperior therapeutics. Dr. Hallam was most recently executive VP of research and development and executive officer at Palatin Technologies. He earned a Ph.D. in biochemistry from King’s College London. Dr. Eric HEDRICK Pharmacyclics Expands Oncology Team Pharmacyclics, a clinical-stage biopharmaceutical company focused on developing and commercializing small-molecule drugs for the treatment of cancer and immune-mediated diseases, has named Eric Hedrick, M.D., VP, oncology clinical development. Dr. Hedrick was previously an independent drug development consultant. Dr. Hedrick received an M.D. from the University of Maryland School of Medicine and is board-certified in medical oncology and internal medicine. Dr. James KARRAS Regulus Therapeutics Names Head of Immunology Regulus Therapeutics, a biopharmaceutical company focused on the discovery and development of medicines targeting microRNAs, has appointed James Karras, Ph.D., senior director of immunology. Dr. Karras is responsible for leading the immunology discovery and research efforts at Regulus, including the company’s immuno-inflammatory alliance with GlaxoSmithKline. Dr. Karras, a trained immunologist with research interests in molecular immunology and allergy and asthma, was previously senior director of clinical science at Altair Therapeutics. He received a Ph.D. in pharmacology and toxicology from the Medical College of Virginia at Virginia Commonwealth University. Dr. David WEBER Otonomy Announces Leadership Shift Otonomy, a clinical-stage biopharmaceutical company developing drug therapies for disorders of the inner and middle ear, has named David Weber, Ph.D., president and CEO. Dr. Weber succeeds Otonomy Co-Founder Jay Lichter, Ph.D., who remains a member of the company’s board. Dr. Weber has more than two decades of life-sciences experience and was the founding CEO of MacuSight. He received a master’s degree in biological sciences from Wichita State University and a Ph.D. from the Creighton University School of Medicine. * Specialty POOL Bob RADIE Topaz Pharmaceuticals Appoints CEO Topaz Pharmaceuticals, a privately held specialty pharmaceutical company, has appointed Bob Radie president and CEO. Interim CEO Thomas Beck, M.D., has resumed his role as Topaz’s chief medical officer. Mr. Radie has more than 25 years of experience in the pharmaceutical and biotechnology industries, most recently as president and CEO of TransMolecular. * Discovery POOL Dr. Michael HANLEY Celtaxsys Taps Former Amylin Executive as CEO Celtaxsys, a privately held start-up focused on discovery and development of therapeutics to treat inflammation, has named Michael Hanley, Ph.D., CEO and chairman. Dr. Hanley has served on Celtaxsys’ scientific advisory board and board of directors since 2007. Dr. Hanley brings to Celtaxsys more than 20 years of managerial experience in the international life-sciences industry, most recently as chief scientific officer for Amylin Pharmaceuticals. He received a Ph.D. in molecular biology from the University of California, Berkeley. * Agency POOL Mark KHAN Axon Expands U.S. Group Axon has further expanded its New York-based pool of talent with the appointment of Mark Khan as VP, client services and business development, of Axon US. Mr. Khan joins Axon from Scientivity, where he was senior director, client services. Axon, part of the National group of companies, provides medical communications, public relations, and clinical research consulting support to the pharmaceutical and medical device industries through offices in London, Toronto, Montreal, and New York. * Consulting POOL Edwin RIVERA-MARTINEZ Parexel Consulting Enhances Regulatory, Compliance Expertise Parexel Consulting, a business unit of Parexel International, has appointed longtime FDA official Edwin Rivera-Martinez as a technical VP to the company’s strategic compliance services team. Mr. Rivera-Martinez joins Parexel after more than 33 years at the FDA, most recently as chief of the FDA’s International Compliance Branch. His appointment further expands the company’s global team of regulatory and compliance experts, which supports biopharmaceutical and medical device clients in navigating the increasingly complex regulatory environment and institutes proactive strategic compliance practices to help guide the success of their products. * CRO POOL Rick CIMINO Jon KOCH Deborah TANNER John WATSON Covance Promotes Four VPs Drug development services provider Covance has announced a number of promotions to its executive team. Rick Cimino has been named executive VP and group president, clinical development. Mr. Cimino leads Phase I to Phase IV clinical operations and is responsible for integrated drug development across the company’s early- and late-stage service offerings. Jon Koch has been promoted to corporate VP and president, central laboratory services, from VP and general manager, discovery and translational services. Mr. Koch succeeds Deborah Tanner, who has been promoted to executive VP and group president, R&D laboratories. John Watson has been promoted to corporate senior VP, president, strategic partnering, and chief commercial officer. Mr. Watson oversees all of Covance’s commercial activities and strategic collaborations with key biopharmaceutical clients. Elena LOGAN PPD Names VP of Global Labs PPD has appointed Elena Logan senior VP of global central labs, providing strategic direction for the CRO’s global central laboratory operations located across three continents. Ms. Logan most recently served as divisional VP at ACM Global Central Laboratory. She received an MBA in pharmaceutical marketing from St. Joseph’s University. Dr. Richard WALOVITCH WorldCare Clinical Promotes Medical Chief to President WorldCare Clinical (WCC), an imaging CRO for clinical trials in the pharmaceutical, biotechnology, and medical device industries, has promoted Richard Walovitch, Ph.D., to president. Dr. Walovitch joined WCC in 2009 as chief medical officer. Dr. Walovitch continues to provide medical leadership for the entire organization, with additional responsibilities for directing WCC’s operations, regulatory, sales, and marketing activities, and helping to define the strategic vision of the company. He received a doctorate in pharmacology from the University of Illinois Medical Center and completed his postdoctoral fellowship at the National Institute on Drug Abuse’s Addiction Research Center in the neurochemistry section. * Medical-Education POOL Tangela ROBINSON Scott SCIRE Physicians’ Education Resource Bolsters Leadership Physicians’ Education Resource (PER), a provider of certified, oncology/hematology-focused continuing medical education (CME), has added two directors to its management team. Tangela Robinson has been named director of marketing, tasked with driving participation in PER’s numerous events and leading PER’s new online, mobile, and social media marketing initiatives. Ms. Robinson was most recently a marketing director for Trammell Crow. Scott Scire has joined PER as senior director, business development. Mr. Scire is responsible for the design of strategic initiatives and for establishing new collaborative opportunities that facilitate the expansion of PER’s live, print, and online educational activities. He was previously a senior VP with OptumHealth Education. * Service POOL Dr. Robert BURFORD Laureate Pharma Establishes Regulatory Affairs Group Laureate Pharma, a full-service biopharmaceutical contract development and manufacturing organization, has appointed Robert Burford, Ph.D., as VP, regulatory affairs, as part of the creation of a regulatory affairs group. Dr. Burford is responsible for establishing and expanding regulatory affairs services to support Laureate clients’ clinical programs. Dr. Burford joins Laureate after 16 years as president of American Clinical Research Consultants. He earned a Ph.D. in pharmacology/toxicology from the University of Western Ontario in Canada. Steven COLLIS AmerisourceBergen Selects President Global pharmaceutical services provider AmerisourceBergen has promoted Steven Collis to president and chief operating officer, from his previous role of executive VP and president of AmerisourceBergen Drug Corporation (ABDC), the company’s largest subsidiary. Mr. Collis is responsible for all AmerisourceBergen business units, including ABDC, AmerisourceBergen Specialty Group (ABSG), AmerisourceBergen Consulting Services (ABCS), and AmerisourceBergen Packaging Group (ABPG). Rob O’TOOLE Precept Life Sciences Makes Leadership Change Clinical research professional services firm Precept Life Sciences has tapped Co-Founder Rob O’Toole to serve as the company’s business head. Mr. O’Toole brings a strong background of related experience in the medical and IT consulting industry, including leadership roles at Vista RMS, IMI Systems, and, most recently, Synergy Services. * Technology POOL Mac MCELROY Cmed Names U.S. CEO U.K.-based Cmed Group has appointed Mac McElroy CEO of its U.S. organization, Cmed Inc., as the group accelerates the global expansion of its flagship clinical data capture and management solution Timaeus. Mr. McElroy previously served as executive director of strategic development, Americas, for Chiltern International.